SPY437.98-8.77 -1.96%
DIA342.35-4.72 -1.36%
IXIC13,768.92-385.10 -2.72%

BRIEF-NRx Pharma Files Breakthrough Therapy Designation Request for ZYESAMI® in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

reuters.com · 12/29/2021 06:56
BRIEF-NRx Pharma Files Breakthrough Therapy Designation Request for ZYESAMI® in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

- NRX Pharmaceuticals Inc NRXP:

  • NRX PHARMACEUTICALS FILES BREAKTHROUGH THERAPY DESIGNATION REQUEST FOR ZYESAMI® (AVIPTADIL) IN PATIENTS AT IMMEDIATE RISK OF DEATH FROM COVID-19 DESPITE TREATMENT WITH REMDESIVIR AND OTHER APPROVED THERAPIES

  • NRX PHARMACEUTICALS - REQUEST FOCUSED ON PATIENTS WHOSE RESPIRATORY FAILURE HAS PROGRESSED DESPITE TREATMENT WITH REMDESIVIR

  • NRX PHARMACEUTICALS - FILING IS BASED ON FDA REQUEST FOR CLINICAL DATA ON EFFECTIVENESS OF ZYESAMI COMPARED TO REMDESIVIR AND OTHER APPROVED THERAPIES

Source text for Eikon: ID:nPn1ZBDY9a

Further company coverage: NRXP


((Reuters.Briefs@thomsonreuters.com;;))